- Home
- ANGO vs YMAB Comparison
ANGO vs YMAB Comparison
Compare ANGO & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGO
- YMAB
- Stock Information
- Founded
- ANGO 1988
- YMAB 2015
- Country
- ANGO United States
- YMAB United States
- Employees
- ANGO N/A
- YMAB N/A
- Industry
- ANGO Medical/Dental Instruments
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- ANGO Health Care
- YMAB Health Care
- Exchange
- ANGO Nasdaq
- YMAB Nasdaq
- Market Cap
- ANGO 279.1M
- YMAB 270.5M
- IPO Year
- ANGO 2004
- YMAB 2018
- Fundamental
- Price
- ANGO $9.78
- YMAB $4.88
- Analyst Decision
- ANGO Strong Buy
- YMAB Buy
- Analyst Count
- ANGO 3
- YMAB 11
- Target Price
- ANGO $13.00
- YMAB $19.64
- AVG Volume (30 Days)
- ANGO 511.4K
- YMAB 333.1K
- Earning Date
- ANGO 04-02-2025
- YMAB 03-04-2025
- Dividend Yield
- ANGO N/A
- YMAB N/A
- EPS Growth
- ANGO N/A
- YMAB N/A
- EPS
- ANGO N/A
- YMAB N/A
- Revenue
- ANGO $286,498,000.00
- YMAB $87,685,000.00
- Revenue This Year
- ANGO N/A
- YMAB $20.07
- Revenue Next Year
- ANGO $6.63
- YMAB $8.76
- P/E Ratio
- ANGO N/A
- YMAB N/A
- Revenue Growth
- ANGO N/A
- YMAB 3.38
- 52 Week Low
- ANGO $5.26
- YMAB $4.25
- 52 Week High
- ANGO $13.50
- YMAB $17.78
- Technical
- Relative Strength Index (RSI)
- ANGO 48.76
- YMAB 40.52
- Support Level
- ANGO $8.95
- YMAB $4.45
- Resistance Level
- ANGO $9.84
- YMAB $5.03
- Average True Range (ATR)
- ANGO 0.47
- YMAB 0.39
- MACD
- ANGO 0.09
- YMAB 0.02
- Stochastic Oscillator
- ANGO 85.99
- YMAB 48.15
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.